The incidence of these common adverse reactions was lower in the surveillance program than in the controlled clinical studies:The following adverse reactions have been reported in post-marketing experience or with an incidence of less than 1% of patients in clinical trials with the 10 mg tablet:Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of Cyclobenzaprine toxicity.Other potential effects of overdosage include any of the symptoms listed under In order to protect against the rare but potentially critical manifestations described above, obtain an ECG and immediately initiate cardiac monitoring. Physician-assessed secondary endpoints also showed that Cyclobenzaprine hydrochloride 5 mg was associated with a greater reduction in palpable muscle spasm than placebo.Analysis of the data from controlled studies shows that Cyclobenzaprine hydrochloride produces clinical improvement whether or not sedation occurs.Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.Cyclobenzaprine hydrochloride tablets, USP has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy.Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. Such insertions do not conform to our The following information includes only the average doses of this medicine. Includes indications, proper use, special instructions, precautions, and possible side effects. All orders will be subject to courier charges and supplies are normally dispatched through internationally accredited courier services.Comments should be on the topic and should not be abusive. If signs of toxicity occur at any time during this period, extended monitoring is required. Cyclobenzaprine is used short-term to treat muscle spasms. In short term studies for indications other than muscle spasm associated with acute musculoskeletal conditions, and usually at doses somewhat greater than those recommended for skeletal muscle spasm, some of the more serious central nervous system reactions noted with the tricyclic antidepressants have occurred (see Tricyclic antidepressants have been reported to produce arrhythmias, sinus tachycardia, prolongation of the conduction time leading to myocardial infarction and stroke.Cyclobenzaprine hydrochloride may enhance the effects of alcohol, barbiturates, and other CNS depressants.Patients should be cautioned about the risk of serotonin syndrome with the concomitant use of Cyclobenzaprine hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. Patients should be advised of the signs and symptoms of serotonin syndrome, and be instructed to seek medical care immediately if they experience these symptoms (see Cyclobenzaprine hydrochloride may enhance the effects of alcohol, barbiturates, and other CNS depressants.Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol.Cyclobenzaprine did not affect the onset, incidence or distribution of neoplasia in an 81-week study in the mouse or in a 105-week study in the rat.At oral doses of up to 10 times the human dose, Cyclobenzaprine did not adversely affect the reproductive performance or fertility of male or female rats. • Caution should be exercised in patients with history of overactive thyroid, heart disease, increased eye pressure, difficulty in urinating, liver problems, cerebral palsy, brain or spinal cord disease, stroke, any allergy, who are taking other medications, elderly, children, during pregnancy and breast feeding. No well-controlled studies have been performed to indicate that Cyclobenzaprine hydrochloride enhances the clinical effect of aspirin or other analgesics, or whether analgesics enhance the clinical effect of Cyclobenzaprine hydrochloride in acute musculoskeletal conditions.Although the frequency and severity of adverse reactions observed in patients treated with Cyclobenzaprine hydrochloride were comparable to those observed in patients treated with diazepam, dry mouth was observed more frequently in patients treated with Cyclobenzaprine hydrochloride and dizziness more frequently in those treated with diazepam. The incidence of drowsiness, the most frequent adverse reaction, was similar with both drugs.The efficacy of Cyclobenzaprine hydrochloride  5 mg was demonstrated in two seven-day, double-blind, controlled clinical trials enrolling 1405 patients.